Cover Image
市場調查報告書

PharmaPoint:心臟衰竭 (HF) - 全球醫藥品市場預測與市場分析

PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026

出版商 GlobalData 商品編碼 296455
出版日期 內容資訊 英文 241 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:心臟衰竭 (HF) - 全球醫藥品市場預測與市場分析 PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026
出版日期: 2017年07月01日 內容資訊: 英文 241 Pages
簡介

主要7個國家 (美國,法國,德國,義大利,西班牙,英國,日本) 的心臟衰竭 (HF) 治療藥市場銷售額,預計從2016年的37億美元,擴大到2026年的161億美元。預計市場2016年∼2026年以15.7%的年複合成長率 (CAGR) 成長。

本報告提供心臟衰竭 (HF) 治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 疾病概要

  • 病因、病理生理學
  • 分類、病期分類系統
  • 症狀
  • 預後
  • QOL

第5章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 資訊來源
    • 預測的前提條件與手法
    • 確診的發病數量
    • 住院期間
    • 確診的患者數等
  • 流行病學預測
  • 議論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第6章 疾病的管理

  • 診斷概要
  • 治療概要
  • 美國
  • EU5個國家
  • 日本

第7章 競爭評估

  • 概要
  • ACE抑制劑 (ACEI)
  • 血管收縮素受體阻斷劑 (ARB)
  • Entresto
  • 利尿劑
  • 乙型阻斷劑
  • Procoralan (Ivabradine)
  • 鹽皮質激素受體拮抗劑
  • 地高辛
  • 急性心臟衰竭 (AHF)的藥物療法

第8章 未滿足需求和機會

  • 概要
  • HF-PEF患者缺乏治療方法
  • AHF缺乏治療方法
  • 腎臟功能障礙患者缺乏治療方法
  • HF對有進行風險的患者的預防療法
  • HF療法的恰當有效利用等

第9章 開發平台評估

  • 概要
  • 臨床開發中的藥物
  • 臨床開發中的潛力藥物
  • Omecamtiv Mecarbil
    • 概要
    • 有效性
    • 安全性
    • 投藥、處方
    • 潛在的臨床/商業性定位
    • SWOT分析
    • 預測
  • Vericiguat
  • RT-100
  • CXL-1427
  • 開發中的其他藥劑

第10章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • Amgen and Cytokinetics
  • Bayer (及 Merck. Co.)
  • Bristol-Myers Squibb
  • Les Laboratoires Servier
  • Novartis
  • Renova Therapeutics

第11章 市場預測

  • 全球市場
  • 美國
  • EU5個國家
  • 日本

第12章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC146PIDR

Heart failure (HF) is a universal condition affecting people of all ages, but which is found most frequently in those over the age of 65 years. Although HF is manageable and significant breakthroughs in the treatment of chronic HF have been made in the past few decades, the condition still carries a poorer prognosis and quality of life than certain types of cancers. Moreover, the prevalence of HF is on the rise due to the aging global population; the increased prevalence of diabetes, obesity, and hypertension; and improved treatment and survival after myocardial infarction (MI).

It is estimated that the sales of HF therapeutics to be approximately US$3.7B across the 7MM in 2016. By 2026, the HF market expects to grow at a strong Compound Annual Growth Rate (CAGR) of 15.7%, reaching sales of US$16.1B by the end of the forecast period. Chronic HF therapeutics accounted for 95.9% of the total HF market in 2015, and despite the launch of a new acute HF therapy, this figure is expected to increase slightly to 98.7% by 2026. Novartis' Entresto will be the strongest driver of the chronic HF and total HF markets in the 7MM, reaching peak sales of US$8.6B in 2022.

Major drivers of HF market growth over the forecast period are the -

  • Launch of Novartis' first-in-class angiotensin receptor-neprilysin inhibitor (ARNi), Entresto, in the US in 2015, 5EU in 2016, and Japan in 2020, significantly boosting market growth.
  • Launch of several chronic HF add-on therapies, including Amgen and Cytokinetics' omecamtiv mecarbil.
  • Increase in the global prevalence of chronic HF and in the incidence of acute HF.

The 7MM chronic HF market size in 2016 was US$3.6B, and is expected to increase to US$15.6B by 2026 at a CAGR of 16.1%. The US was the largest market for chronic HF therapies, contributing 73.4% of total sales in the base year.

The report "PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2026" provides a detailed analysis of the current HF market and indicates how it will evolve over the next decade following the launch of several new therapies. Moreover, it also highlights the major unmet needs in the HF space and provides strategic insights into how drug developers can target these lucrative opportunities.

Specifically, this report enables the following -

  • Overview of HF, both chronic and acute, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the chronic and acute HF therapeutics markets.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global HF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: Amgen, Bayer, BMS, Cardiorentis, Cytokinetics, Les Laboratoires Servier, Merck & Co., Novartis, Ono Pharmaceuticals, Pfizer.

Scope:

  • Overview of HF, both chronic and acute, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized HF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the chronic and acute HF therapeutics markets.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global HF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy:

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the HF therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HF therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the 7MM HF therapeutics market from 2016-2026.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Heart Failure: Executive Summary

  • 2.1. The HF Market Will Exhibit Strong Growth Between 2016 and 2026
  • 2.2. Label Expansion to HF with Preserved Ejection Fraction Will Fuel Market Growth
  • 2.3. The HF Market Has Considerable Unmet Needs, Despite the Availability of Well-Established Therapies and a Promising Pipeline
  • 2.4. Opportunities Remain for All Aspects of HF, But What the Market Really Needs Is a Transformational Therapy
  • 2.5. Entresto Will Dominate the HF Market
  • 2.6. What Do Physicians Think?

3. Introduction

  • 3.1. Catalyst
  • 3.2. Related Reports

4. Disease Overview

  • 4.1. Etiology and Pathophysiology
    • 4.1.1. Etiology
    • 4.1.2. Pathophysiology
    • 4.1.3. Biomarkers/Targets of Interest
  • 4.2. Classification or Staging Systems
  • 4.3. Symptoms
  • 4.4. Prognosis
  • 4.5. Quality of Life

5. Epidemiology

  • 5.1. Disease Background
  • 5.2. Risk Factors and Comorbidities
  • 5.3. Global and Historical Trends
  • 5.4. Forecast Methodology
    • 5.4.1. Sources
    • 5.4.2. Forecast assumptions and methods
    • 5.4.3. Diagnosed Incident Cases of HF by EF
    • 5.4.4. Diagnosed Incident Cases of HF by Ventricular Dysfunction
    • 5.4.5. Acute HF Hospitalizations
    • 5.4.6. Hospital Length of Stay for Acute HF Hospitalization
    • 5.4.7. Diagnosed Prevalent Cases of CHF
    • 5.4.8. Diagnosed Prevalent Cases of CHF by EF
    • 5.4.9. Diagnosed Prevalent Cases of CHF by NYHA Classes
  • 5.5. Epidemiological Forecast for Heart Failure (2016-2026)
    • 5.5.1. Diagnosed Incident Cases of HF
    • 5.5.2. Age-Specific Diagnosed Incident Cases of HF
    • 5.5.3. Sex-Specific Diagnosed Incident Cases of HF
    • 5.5.4. Diagnosed Incident Cases of HF by EF
    • 5.5.5. Diagnosed Incident Cases of HF by VD
    • 5.5.6. Acute HF Hospitalizations
    • 5.5.7. Hospital Length of Stay for Acute HF Hospitalization
    • 5.5.8. Diagnosed Prevalent Cases of CHF
    • 5.5.9. Age-Specific Diagnosed Prevalent Cases of CHF
    • 5.5.10. Sex-Specific Diagnosed Prevalent Cases of CHF
    • 5.5.11. Diagnosed Prevalent Cases of CHF by EF
    • 5.5.12. Diagnosed Prevalent Cases of CHF by NYHA Class
  • 5.6. Discussion
    • 5.6.1. Epidemiological Forecast Insight
    • 5.6.2. Limitations of Analysis
    • 5.6.3. Strengths of Analysis

6. Disease Management

  • 6.1. Diagnosis Overview
  • 6.2. Treatment Overview
    • 6.2.1. Treatment Guidelines and Leading Prescribed Drugs
    • 6.2.2. Clinical Practice
  • 6.3. US
  • 6.4. 5EU
  • 6.5. Japan

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Angiotensin-Converting Enzyme Inhibitors
    • 7.2.1. Overview
    • 7.2.2. Efficacy
    • 7.2.3. Safety
    • 7.2.4. Forecast
  • 7.3. Angiotensin Receptor Blockers
    • 7.3.1. Overview
    • 7.3.2. Efficacy
    • 7.3.3. Safety
    • 7.3.4. Forecast
  • 7.4. Entresto (Sacubitril + Valsartan)
    • 7.4.1. Overview
    • 7.4.2. Efficacy
    • 7.4.3. Safety
    • 7.4.4. SWOT Analysis
    • 7.4.5. Forecast
  • 7.5. Diuretics
    • 7.5.1. Overview
    • 7.5.2. Efficacy
    • 7.5.3. Safety
    • 7.5.4. Forecast
  • 7.6. Beta Blockers
    • 7.6.1. Overview
    • 7.6.2. Efficacy
    • 7.6.3. Safety
    • 7.6.4. Forecast
  • 7.7. Procoralan (Ivabradine)
    • 7.7.1. Overview
    • 7.7.2. Efficacy
    • 7.7.3. Safety
    • 7.7.4. SWOT Analysis
    • 7.7.5. Forecast
  • 7.8. Mineralocorticoid Receptor Antagonists
    • 7.8.1. Overview
    • 7.8.2. Efficacy
    • 7.8.3. Safety
    • 7.8.4. Forecast
  • 7.9. Digoxin
    • 7.9.1. Overview
    • 7.9.2. Efficacy
    • 7.9.3. Safety
    • 7.9.4. Forecast
  • 7.10. Pharmacological Therapies for Acute HF

8. Unmet Needs and Opportunity Assessment

  • 8.1. Overview
  • 8.2. Lack of Therapies for HF-PEF Patients
    • 8.2.1. Unmet Need
    • 8.2.2. Gap Analysis
    • 8.2.3. Opportunity
  • 8.3. Lack of Therapies for Acute HF
    • 8.3.1. Unmet Need
    • 8.3.2. Gap Analysis
    • 8.3.3. Opportunity
  • 8.4. Lack of Therapies for Patients with Renal Impairment
    • 8.4.1. Unmet Need
    • 8.4.2. Gap Analysis
    • 8.4.3. Opportunity
  • 8.5. Preventative Therapies for Patients at Risk of Developing HF
    • 8.5.1. Unmet Need
    • 8.5.2. Gap Analysis
    • 8.5.3. Opportunity
  • 8.6. Use of Optimal Doses of HF Therapies
    • 8.6.1. Unmet Need
    • 8.6.2. Gap Analysis
    • 8.6.3. Opportunity
  • 8.7. Patient Compliance
    • 8.7.1. Unmet Need
    • 8.7.2. Gap Analysis
    • 8.7.3. Opportunity
  • 8.8. Early Detection and Treatment of Patients with Worsening Chronic HF
    • 8.8.1. Unmet Need
    • 8.8.2. Gap Analysis
    • 8.8.3. Opportunity
  • 8.9. Dynamic Management of Patients with HF
    • 8.9.1. Unmet Need
    • 8.9.2. Gap Analysis
    • 8.9.3. Opportunity
  • 8.10. Options for Advanced HF Patients Who Are Unable to Receive a Heart Transplant
    • 8.10.1. Unmet Need
    • 8.10.2. Gap Analysis
    • 8.10.3. Opportunity
  • 8.11. Better Risk Stratification of Patients Admitted to the ED with Acute HF and Enhanced Outpatient Care
    • 8.11.1. Unmet Need
    • 8.11.2. Gap Analysis
    • 8.11.3. Opportunity

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Drugs in Clinical Development
    • 9.2.1. Pipeline Drugs by Patient Population
  • 9.3. Promising Drugs in Clinical Development
  • 9.4. Omecamtiv Mecarbil
    • 9.4.1. Overview
    • 9.4.2. Efficacy
    • 9.4.3. Safety
    • 9.4.4. Dosing and Formulation
    • 9.4.5. Potential Clinical and Commercial Positioning
    • 9.4.6. SWOT Analysis
    • 9.4.7. Forecast
  • 9.5. Vericiguat
    • 9.5.1. Overview
    • 9.5.2. Efficacy
    • 9.5.3. Safety
    • 9.5.4. Dosing and Formulation
    • 9.5.5. Potential Clinical and Commercial Positioning
    • 9.5.6. SWOT Analysis
    • 9.5.7. Forecast
  • 9.6. RT-100
    • 9.6.1. Overview
    • 9.6.2. Efficacy
    • 9.6.3. Safety
    • 9.6.4. Dosing and Formulation
    • 9.6.5. Potential Clinical and Commercial Positioning
    • 9.6.6. SWOT Analysis
    • 9.6.7. Forecast
  • 9.7. CXL-1427
    • 9.7.1. Overview
    • 9.7.2. Efficacy
    • 9.7.3. Safety
    • 9.7.4. Dosing and Formulation
    • 9.7.5. Potential Clinical and Commercial Positioning
    • 9.7.6. SWOT Analysis
    • 9.7.7. Forecast
  • 9.8. Other Drugs in Development

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Amgen and Cytokinetics
    • 10.3.1. Overview
    • 10.3.2. Portfolio Assessment
  • 10.4. Bayer (and Merck & Co.)
    • 10.4.1. Overview
    • 10.4.2. Portfolio Assessment
  • 10.5. Bristol-Myers Squibb
    • 10.5.1. Overview
    • 10.5.2. Portfolio Assessment
  • 10.6. Les Laboratoires Servier
    • 10.6.1. Overview
    • 10.6.2. Portfolio Assessment
  • 10.7. Novartis
    • 10.7.1. Overview
    • 10.7.2. Portfolio Assessment
  • 10.8. Renova Therapeutics
    • 10.8.1. Overview
    • 10.8.2. Portfolio Assessment

11. Market Outlook

  • 11.1. Global Markets
    • 11.1.1. Forecast
    • 11.1.2. Drivers and Barriers - Global Issues
  • 11.2. US
    • 11.2.1. Forecast
    • 11.2.2. Key Events
    • 11.2.3. Drivers and Barriers
  • 11.3. 5EU
    • 11.3.1. Forecast
    • 11.3.2. Key Events
    • 11.3.3. Drivers and Barriers
  • 11.4. Japan
    • 11.4.1. Forecast
    • 11.4.2. Key Events
    • 11.4.3. Drivers and Barriers

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Methodology
    • 12.3.1. Forecasting Methodology
    • 12.3.2. Diagnosed Prevalent Chronic HF
    • 12.3.3. Diagnosed Incidence of Acute HF
    • 12.3.4. Percent Drug-Treated Patients
    • 12.3.5. Treatment of HF with Reduced Ejection Fraction Versus HF with Preserved Ejection Fraction
    • 12.3.6. Drugs Included in Each Therapeutic Class
    • 12.3.7. Launch and Patent Expiry Dates
    • 12.3.8. General Pricing Assumptions
    • 12.3.9. Individual Drug Assumptions
    • 12.3.10. Generic Erosion
    • 12.3.11. Pricing of Pipeline Agents
  • 12.4. Primary Research - KOLs Interviewed for this Report
  • 12.5. Primary Research - Payers Included in this Study
  • 12.6. Primary Research - Prescriber Survey
  • 12.7. About the Authors
    • 12.7.1. Analyst
    • 12.7.2. Therapy Area Director
    • 12.7.3. Epidemiologist
    • 12.7.4. Managing Epidemiologists
    • 12.7.5. Global Director of Therapy Analysis and Epidemiology
    • 12.7.6. Global Head and EVP of Healthcare Operations and Strategy
  • 12.8. About GlobalData
  • 12.9. Contact Us
  • 12.10. Disclaimer

List of Tables

  • Table 1: Heart Failure: Key Metrics in the 7MM
  • Table 2: Types of Chronic HF
  • Table 3: The leading causes, as well as other less common causes, of HF.
  • Table 4: The compensatory mechanisms that are activated in a patient with HF.
  • Table 5: Key Diagnostic and prognostic biomarkers in HF.
  • Table 6: Overview of Clinically Relevant Biomarkers in HF
  • Table 7: shows a comparison of these two HF classification systems.
  • Table 8: Symptoms of Heart Failure
  • Table 9: Risk Factors and Comorbidities for HF
  • Table 10: NYHA Functional Classification for CHF (Classes I-IV).
  • Table 11: 7MM, Diagnosed Incident Cases of HF, Both Sexes, Ages ≥45 Years, N, Selected Years 2016-2026
  • Table 12: 7MM, Diagnosed Prevalent Cases of CHF, Both Sexes, Ages ≥45 Years, N, Selected Years 2016-2026
  • Table 13: lists the common factors that precipitate acute HF.
  • Table 14: HF Treatment guidelines most commonly adhered to by physicians in the 7MM.
  • Table 15: summarizes the chronic HF-REF medications and drug classes most commonly used in the US, 5EU, and Japan, based on GlobalData's primary and secondary research.
  • Table 16: Country Profile - US
  • Table 17: Country Profile - 5EU
  • Table 18: Country Profile - Japan
  • Table 19: Summary of major clinical trials assessing the efficacy of ACE inhibitors in HF-REF patients.
  • Table 20: Summary of major clinical trials assessing the efficacy of ARBs in HF-REF patients.
  • Table 21: Product Profile - Entresto
  • Table 22: Efficacy of Entresto, PARADIGM-HF
  • Table 23: Safety of Entresto, PARADIGM-HF
  • Table 24: Entresto SWOT Analysis, 2016
  • Table 25: Summary of major clinical trials assessing the efficacy of beta blockers in HF-REF patients.
  • Table 26: Product Profile - Procoralan
  • Table 27: Efficacy of Procoralan, SHIFT study
  • Table 28: Procoralan SWOT Analysis, 2016
  • Table 29: Unmet Need and Opportunity in HF, 2016
  • Table 30: Product Profile - Omecamtiv Mecarbil
  • Table 31: Efficacy of Omecamtiv Mecarbil, COSMIC-HF
  • Table 32: Omecamtiv Mecarbil SWOT Analysis, 2016
  • Table 33: Product Profile - Vericiguat
  • Table 34: Efficacy of Vericiguat, SOCRATES-Reduced
  • Table 35: Safety of Vericiguat, SOCRATES-Reduced
  • Table 36: Vericiguat SWOT Analysis, 2016
  • Table 37: Product Profile - RT-100
  • Table 38: RT-100 SWOT Analysis, 2016
  • Table 39: Product Profile - CXL-1427
  • Table 40: CXL-1427 SWOT Analysis, 2016
  • Table 41: Drugs in Development for Heart Failure, 2016
  • Table 42: Key Companies in the Heart Failure Market in the 7MM, 2016
  • Table 43: Amgen's HF Portfolio Assessment, 2016
  • Table 44: Bayer's HF Portfolio Assessment, 2016
  • Table 45: Bristol-Myers Squibb HF Portfolio Assessment, 2016
  • Table 46: Servier's HF Portfolio Assessment, 2016
  • Table 47: Novartis' Disease Portfolio Assessment, 2016
  • Table 48: Renova Therapeutics' Disease Portfolio Assessment, 2016
  • Table 49: Heart Failure Market - Global Drivers and Barriers, 2016-2026
  • Table 50: Key Events Impacting Sales for HF in the US, 2016-2026
  • Table 51: HF Market - Global Drivers and Barriers in the US, 2016-2026
  • Table 52: Key Events Impacting Sales for Heart Failure in the 5EU, 2016-2026
  • Table 53: Heart Failure Market - Global Drivers and Barriers in the 5EU, 2016-2026
  • Table 54: Key Events Impacting Sales for Heart Failure in Japan, 2016-2026
  • Table 55: Heart Failure Market - Global Drivers and Barriers in Japan, 2016-2026
  • Table 56: Key Historical and Projected Launch Dates for HF
  • Table 57: Key Historical and Projected Patent Expiry Dates for Heart Failure
  • Table 58: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for Heart Failure by Country, 2016 and 2026
  • Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Heart Failure, 2016-2026
  • Figure 3: Changes in Cardiac Structure in HF
  • Figure 4: RAAS Mechanism of Action
  • Figure 5: 7MM, Age-Standardized Diagnosed Incidence of HF (Cases per 100,000 Population), Men and Women, Ages ≥45 Years, 2016
  • Figure 6: 7MM, Age-Standardized Diagnosed Prevalence of CHF (%), Men and Women, Ages ≥45 Years, 2016
  • Figure 7: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF
  • Figure 8: 7MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of CHF
  • Figure 9: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF by EF
  • Figure 10: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by EF
  • Figure 11: 7MM, Sources Used to Forecast Diagnosed Incident Cases of HF by Ventricular Dysfunction
  • Figure 12: 7MM, Sources Used to Forecast Hospitalizations for Acute HF
  • Figure 13: 7MM, Sources Used to Forecast Hospitalizations for Acute HF by Worsening CHF, Advanced HF, and de novo HF
  • Figure 14: 7MM, Sources Used to Forecast Hospital Length of Stay for Acute HF Hospitalization
  • Figure 15: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of CHF by NYHA Class
  • Figure 16: 7MM, Age-Specific Diagnosed Incident Cases of HF, Both Sexes, Ages ≥45 Years, N, 2016
  • Figure 17: 7MM, Sex-Specific Diagnosed Incident Cases of HF, Ages ≥45 Years, N, 2016
  • Figure 18: 7MM, Diagnosed Incident Cases of HF by EF, Both Sexes, Ages ≥45 Years, N, 2016
  • Figure 19: 7MM, Diagnosed Incident Cases of HF by VD, Both Sexes, Ages ≥45 Years, N, 2016
  • Figure 20: 7MM, Acute HF Hospitalizations, Both Sexes, Ages ≥45 Years, N, 2016 to 2026
  • Figure 21: 7MM, Acute HF Hospitalizations by Patients Admitted and Discharged, Both Sexes, Ages ≥45 Years, 2016
  • Figure 22: 7MM, Acute HF Hospitalizations by Worsening Chronic HF, Advanced HF, and De Novo HF, Both Sexes, Ages ≥45 Years, 2016
  • Figure 23: 7MM, Hospital Length of Stay for Acute HF Hospitalization, Both Sexes, Ages ≥45 Years, N, 2016
  • Figure 24: 7MM, Age-Specific Diagnosed Prevalent Cases of CHF, Both Sexes, Ages ≥45 Years, N, 2016
  • Figure 25: 7MM, Sex-Specific Diagnosed Prevalent Cases of CHF, Both Sexes, Ages ≥45 Years, N, 2016
  • Figure 26: 7MM, Diagnosed Prevalent Cases of CHF by EF, Both Sexes, Ages ≥45 Years, N, 2016
  • Figure 27: 7MM, Diagnosed Prevalent Cases of CHF by NYHA Class, Both Sexes, Ages ≥45 Years, N, 2016
  • Figure 28: 7MM, Diagnosed Prevalent Cases of CHF with REF by NYHA Class, Both Sexes, Ages ≥45 Years, N, 2016
  • Figure 29: 7MM, Diagnosed Prevalent Cases of CHF with PEF by NYHA Class, Both Sexes, Ages ≥45 Years, N, 2016
  • Figure 30: Diagnostic Algorithm for Chronic HF
  • Figure 31: Diagnostic Algorithm for Acute HF
  • Figure 32: HF based on the ACCF/AHA staging system
  • Figure 33: Classification of acute HF patients
  • Figure 34: Management of acute HF patients
  • Figure 35: Heart Failure - Drugs in Development, 2016
  • Figure 36: Competitive Assessment of Late-Stage Pipeline Agents in Heart Failure, 2016-2026
  • Figure 37: Company Portfolio Gap Analysis in Heart Failure, 2016-2026
  • Figure 38: Global Sales for Chronic HF by Country, 2016 and 2026
  • Figure 39: Global Sales for acute HF by Country, 2016 and 2026
  • Figure 40: Sales for Chronic HF by Drug Class in the US, 2016 and 2026
  • Figure 41: Sales for Chronic HF by Drug Class in the 5EU, 2016 and 2026
  • Figure 42: Sales for HF by Drug Class in Japan, 2016 and 2026
Back to Top